SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AGEN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Constant Reader who wrote (8)10/15/2001 11:00:18 PM
From: Harry J.  Read Replies (1) of 15
 
Thread (& CR) - "Antigenics' Oncophage(R) Becomes First Personalized Cancer Product To Receive FDA Fast Track Designation"

"NEW YORK, Oct 15, 2001 /PRNewswire via COMTEX/ -- Antigenics Inc. (Nasdaq: AGEN chart, msgs) announced today that the U.S. Food and Drug Administration (FDA) has designated Oncophage(R), the company's personalized cancer vaccine, a Fast Track Product for the treatment of renal cell carcinoma.

[snip]"

Go to SI:News for AGEN to see the rest of the press release.

Regards,
Harry
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News